GemPharmatech Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 2/6
GemPharmatech has been growing earnings at an average annual rate of 29%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 26.4% per year. GemPharmatech's return on equity is 7.6%, and it has net margins of 25.5%.
Key information
29.0%
Earnings growth rate
12.6%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 26.4% |
| Return on equity | 7.6% |
| Net Margin | 25.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How GemPharmatech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 622 | 159 | 0 | 0 |
| 30 Sep 23 | 585 | 154 | 201 | 97 |
| 30 Jun 23 | 562 | 161 | 196 | 95 |
| 31 Mar 23 | 541 | 165 | 187 | 89 |
| 31 Dec 22 | 517 | 165 | 183 | 83 |
| 30 Sep 22 | 500 | 168 | 173 | 79 |
| 30 Jun 22 | 466 | 160 | 165 | 70 |
| 31 Mar 22 | 433 | 137 | 155 | 62 |
| 31 Dec 21 | 394 | 125 | 139 | 55 |
| 31 Dec 20 | 262 | 76 | 83 | 48 |
| 31 Dec 19 | 193 | 30 | 73 | 30 |
| 31 Dec 18 | 53 | -6 | 35 | 11 |
Quality Earnings: 688046 has high quality earnings.
Growing Profit Margin: 688046's current net profit margins (25.5%) are lower than last year (31.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688046 has become profitable over the past 5 years, growing earnings by 29% per year.
Accelerating Growth: 688046's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688046 had negative earnings growth (-3.5%) over the past year, making it difficult to compare to the Life Sciences industry average (0.7%).
Return on Equity
High ROE: 688046's Return on Equity (7.6%) is considered low.